Dutasteride vs Finasteride: How the Range of 5α-Reductase Inhibition Differs — and Where Stem Cell Conditioned Media Fits as a Complement to the Follicular Microenvironment2026.07.08
“Dutasteride or finasteride — which should I choose to start AGA treatment?” This is one of the most common questions in our clinic. Both belong to the 5α-reductase inhibitor class, but they differ clearly in which isozyme they inhibit, how strongly they suppress DHT, and in their side effect profile. There is also a third piece of the puzzle: when the response to dutasteride or finasteride plateaus, stem cell conditioned media offers a complementary approach that acts on the follicular microenvironment itself. This article organizes the position of these three within the overall design of AGA treatment.
Key Points
・Dutasteride inhibits both type I and type II of 5α-reductase, while finasteride selectively inhibits type II only.
・Serum DHT suppression is reported at around 70% with finasteride and over 90% with dutasteride — a real difference in the strength of the effect.
・Follicular micro-inflammation, blood flow, and the growth factor environment include layers that DHT suppression alone cannot address; stem cell conditioned media is positioned as a complementary approach acting on the follicular microenvironment itself.
・When medications and procedures are stacked without a designed order and clear evaluation points, effects don’t accumulate and it becomes harder to judge what is working.
・Dutasteride and finasteride are generally not prescribed to women (particularly those of childbearing potential), so female hair loss requires a different treatment design.
Dutasteride and Finasteride: Breaking Down Their Mechanisms
The main driver of AGA (male pattern hair loss) is the conversion of testosterone to DHT (dihydrotestosterone) by 5α-reductase, followed by DHT binding to androgen receptors in the hair follicle and shortening the anagen phase of the hair cycle. This 5α-reductase has two isozymes — type I and type II — and around the scalp follicles, type II has traditionally been considered the main actor. Recent findings suggest type I also plays some role.
Finasteride: Selectively Inhibits Type II
Finasteride selectively inhibits 5α-reductase type II. At 1 mg per day orally, it suppresses serum DHT by roughly 70%. In Japan it was approved for AGA in 2005, and long-term efficacy and safety data have accumulated. Improvement in hair density at the vertex and frontal areas has been demonstrated across many comparative trials with significant results.
Dutasteride: Inhibits Both Type I and Type II
Dutasteride inhibits both type I and type II isozymes, suppressing serum DHT by more than approximately 90%. In Japan, an additional AGA indication was approved in 2015. Based on evidence that type I plays some role in the scalp as well, dutasteride tends to be chosen when broader and stronger DHT suppression is desired. Even in cases with limited response to finasteride, switching to dutasteride can yield a new clinical response.
Differences in Effect, Side Effect Profile, and the “Limits” of DHT Suppression
Even within the same 5α-reductase inhibitor class, there are several meaningful differences in real-world effect and side effect patterns worth noting.
How Much Does the Effect Actually Differ?
Head-to-head trials have reported that at 24 weeks, the dutasteride group had significantly greater increases in hair count than the finasteride group. However, this is a difference in mean values, and individual patient responses vary widely. Cases responding well to finasteride do not necessarily need a switch.
Side Effect Patterns and Where the Judgment Lies
Typical side effects reported for both drugs include sexual function symptoms (decreased libido, erectile dysfunction, ejaculatory disorders), breast-related symptoms, and mood changes. The frequency of each is a few percent or less, but some reports suggest that dutasteride — due to its stronger DHT suppression — may show these symptoms slightly more often. Dutasteride also has a much longer half-life (several weeks), which means blood concentrations persist for a while even after discontinuation — an important point for treatment planning.
Proscribing 5α-reductase inhibitors to women, particularly those of childbearing potential, is generally avoided due to concerns about male fetal genital development. Tablet handling must also be avoided, and female hair loss requires an entirely different treatment design.
When You Feel a Plateau on Medication — Stem Cell Conditioned Media as a Complement to the Follicular Microenvironment
Suppressing DHT with 5α-reductase inhibitors is equivalent to easing off the “accelerator” of AGA progression. However, pushing already miniaturized follicles back into the anagen phase, and improving the microenvironment of peri-follicular inflammation, blood flow, and extracellular matrix, are layers that DHT suppression alone often cannot address.
DHT Suppression and the Follicular Microenvironment Are Separate Layers
Even with long-term continuation of finasteride or dutasteride, many patients eventually experience a plateau where improvement stops progressing. Rather than simply increasing the dose or switching drugs at this stage, the concept behind stem cell conditioned media is to act on the environment surrounding the follicle itself. The growth factors (VEGF, IGF-1, HGF, and others) and cytokines contained in conditioned media have been reported at the in vitro and animal study level to potentially act on follicular stem cells and dermal papilla cells — with the intent of suppressing micro-inflammation and reinforcing anagen-prolonging signals. That said, human evidence for hair growth effects remains limited, and we honestly convey that this is not an established first-line treatment.
Combination Therapy Is Designed Through Order and Evaluation Timing
When combining oral medication, topicals, and regenerative medicine, adding them without a designed order makes it very difficult to judge what is working. At our clinic, we typically first stop progression with an oral drug (finasteride or dutasteride) and evaluate the response over 3 to 6 months. Once a plateau or regional response variation becomes clear, we then add scalp injection of stem cell conditioned media. Please also see related columns on hair regenerative medicine here. For general guidelines on AGA treatment, materials from the Japanese Dermatological Association are also useful references.
Frequently Asked Questions
Q. When should I switch from finasteride to dutasteride?
Generally, we consider switching when finasteride has been continued for 6 to 12 months with limited effect, or when progression has not stopped. Recording hair density and hair diameter with photographs and trichoscopy before and after switching, and evaluating with objective measures rather than subjective impression alone, is important.
Q. Are dutasteride and finasteride ever used together?
Combination of drugs in the same class is generally not performed. Since both suppress DHT, their actions overlap; the concern about additional side effects and prolonged half-life tends to outweigh any added benefit. The basic approach is to choose one or the other, and treat the question as one of switching.
Q. If I want to avoid medication due to side effect concerns, can stem cell conditioned media alone improve AGA?
There is currently insufficient human evidence that stem cell conditioned media alone can halt AGA progression. Without DHT suppression, the underlying progression continues. For patients who want to avoid oral medication, we honestly discuss expectations and limits before planning together.
Q. During dutasteride use, what should I be careful about with blood donation or PSA testing?
Dutasteride has a long half-life, and blood donation must be avoided during use and for a set period after discontinuation. Also, PSA values are reduced by approximately half, so when undergoing prostate cancer screening you must inform the medical institution that you are taking dutasteride.
Summary
Dutasteride and finasteride, though both 5α-reductase inhibitors, differ in the range of isozymes they inhibit, the strength of DHT suppression, and side effect patterns. The point is not which one is superior, but how to use them differently based on progression, response, and side effect tolerance. And for the layer of the follicular microenvironment that neither drug can address, stem cell conditioned media provides a complementary approach as an option. When you feel a plateau on monotherapy, the key to deciding the next move is not stacking more drugs but re-evaluating which layer the response is stalling at.
──────────────
Supervising Physician: Shin Moriwaki, MD
Member, Japan Society of Aesthetic Surgery (JSAS) / Member, American Academy of Aesthetic Medicine
ECFMG Certificate (USMLE)
──────────────
📍AVAN TOKYO Ginza Hair Regenerative Medicine
AVAN TOKYO 銀座 毛髪再生医療
English / 中文 / Tiếng Việt available
Inquiries welcome via DM / LINE / Website / Phone.